Teva could shift Copaxone to three-times-weekly dosing as patent cliff approaches
This article was originally published in Scrip
Executive Summary
Positive topline data support a three-times-weekly dosing regime for Teva Pharmaceutical Industries' multiple sclerosis blockbuster Copaxone (glatiramer acetate injection), which could protect the drug's market share when its once-daily formulation faces generic competition in the US starting May 2014.